Therapeutic Specialties Archives

Publication

Age Related Changes in Fractional Elimination Pathways for Drugs: Assessing the Impact of Variable Ontogeny on Metabolic Drug-drug Interactions

The magnitude of any metabolic drug-drug interactions (DDIs) depends on fractional importance of inhibited pathway…

CertaraMay 30, 2013

Publication

Biodistribution and Pharmacokinetics of EGFR-targeted Thiolated Gelatin Nanoparticles Following Systemic Administration in Pancreatic Tumor-bearing Mice

The objective of this study was to evaluate qualitative and quantitative biodistribution of epidermal growth…

CertaraMay 6, 2013

Publication

Brain Extracellular γ-hydroxybutyrate Concentrations are Decreased by L-lactate in Rats: Role in the Treatment of Overdoses

L-lactate represents a potential treatment for GHB overdose by inhibiting GHB renal reabsorption mediated by…

CertaraMay 1, 2013

Publication

Do Children Have the Same Vulnerability to Metabolic Drug-drug Interactions as Adults? A Critical Analysis of the Literature

Many drug–drug interactions (DDIs) in the pediatric population are managed based on data generated in…

CertaraMay 1, 2013

Publication

A Physiologically-based Pharmacokinetic (PBPK) Approach to Evaluate Pharmacokinetics in Patients with Cancer

Potential differences in pharmacokinetics (PK) between healthy subjects and patients with cancer were investigated using…

CertaraApril 1, 2013

Publication

Model-based Drug Development in Oncology: What’s Next?

Model-based estimates of tumor growth inhibition (TGI) metrics have the potential to enhance learning in…

CertaraApril 1, 2013

Publication

Model-supported Development of CS-8635: A Fixed-dose Combination of Olmesartan, Amlodipine, and Hydrochlorothiazide

CS-8635, a fixed-dose triple combination of olmesartan, amlodipine, and hydrochlorothiazide, was developed to address the…

CertaraApril 1, 2013

Publication

Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis

Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2,…

CertaraMarch 28, 2013

Publication

Estimating Time to Disease Progression Comparing Transition Models and Survival Methods—An Analysis of Multiple Sclerosis Data

This article reports an analysis that aims to quantify the effect of fingolimod, an oral…

CertaraMarch 1, 2013

Publication

Systems Pharmacology of the Nerve Growth Factor Pathway: Use of a Systems Biology Model for the Identification of Key Drug Targets Using Sensitivity Analysis and the Integration of Physiology and Pharmacology

The nerve growth factor (NGF) pathway is of great interest as a potential source of…

CertaraFebruary 21, 2013

Therapeutic Specialties

Age Related Changes in Fractional Elimination Pathways for Drugs: Assessing the Impact of Variable Ontogeny on Metabolic Drug-drug Interactions

Biodistribution and Pharmacokinetics of EGFR-targeted Thiolated Gelatin Nanoparticles Following Systemic Administration in Pancreatic Tumor-bearing Mice

Brain Extracellular γ-hydroxybutyrate Concentrations are Decreased by L-lactate in Rats: Role in the Treatment of Overdoses

Do Children Have the Same Vulnerability to Metabolic Drug-drug Interactions as Adults? A Critical Analysis of the Literature

A Physiologically-based Pharmacokinetic (PBPK) Approach to Evaluate Pharmacokinetics in Patients with Cancer

Model-based Drug Development in Oncology: What’s Next?

Model-supported Development of CS-8635: A Fixed-dose Combination of Olmesartan, Amlodipine, and Hydrochlorothiazide

Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis

Estimating Time to Disease Progression Comparing Transition Models and Survival Methods—An Analysis of Multiple Sclerosis Data

Systems Pharmacology of the Nerve Growth Factor Pathway: Use of a Systems Biology Model for the Identification of Key Drug Targets Using Sensitivity Analysis and the Integration of Physiology and Pharmacology

Newsletter sign up

Quick links

Solutions

Contact